Norwood MA, March 8, 2018
Be the Partner joins HIPGEN Consortium.
HIPGEN is a multi-center clinical phase III trial led by Charité - Universitätsmedizin Berlin, sponsored by Pluristem Inc (NASDAQ: PSTI) and funded by the Horizon 2020 program of the European Commission. The project aims at bringing the first regenerative therapy for improving recovery following a surgically treated injury to market approval. The major focus of HIPGEN is patients who are undergoing total or hemi- arthoplasty.
Thomas Klein, Chief Executive Officer of Be the Partner states concerning HIPGEN: “We are thrilled to be part of the HIPGEN consortium with our patient relationship management platform. Be the Partner will deliver valuable information and individual study data to the patients and, if desired, also to family or caregivers during and after the trial. With our strategic patient engagement approach, we will do our best to make the study a success and to include the patients as partners in the research process.”
About Be the Partner
Be the Partner is a web platform for patient relationship management beyond the clinical development of pharmaceutical products. Be the Partner provides a means for engaging actual trial participants, post-trial participants (trial alumni) and future trial participants, designers and patient advocates while maintaining required patient anonymity. Be the Partner adds value to the actual services of biopharmaceutical companies, their vendors, sites and investigators that work inside clinical trials while bringing new and unique patient-centric services outside the trial.